About US
Contact us
-
Mylan faces FTC antitrust probe over generic-thwarting EpiPen tweaksMylan’s EpiPen saga isn’t over. After a series of Congressionaldemandsand hearings, back-and-forth with government officials, and a tentative settlement with the Justice Department over Medicaid overc2017/2/17
-
AZ nabs 6 more months of Symbicort exclusivity—and the sales that come with itAstraZeneca’s aging respiratory giant Symbicort won a coveted pediatric exclusivity nod from the FDA on Wednesday, giving the brand a longer life—and potentially hundreds of millions in additional sal2017/2/16
-
Teva faces billions in lost sales as court tosses four long-acting Copaxone patentsIt’s déjà vu for Teva Pharmaceutical in a bad, bad way. Late Monday, the Israeli drugmakerconfirmedthat the U.S. District Court for the District of Delaware had upturned four of its patents on the lo2017/2/16
-
Inherited pay-for-delay penalties are getting expensive for 'cash-strapped' TevaTeva is eager to start moving in the right direction after a particularly rocky 2016. Problem is, it’s still paying for pay-for-delay decisions made by its products’ previous owners. Both Paul Bisaro2017/2/15
-
Sandoz head: Enbrel biosimilar Erelzi won't launch before 2018, delayed by legal battleNovartis CEO Joe Jimenez today pointed to the company’s biosimilars program as being one buffer if President Trump’s threat to cut drug prices should materialize into some action. The drugmaker has tw2017/2/15
-
Government still has 'no settlement' with Mylan, CMS administrator saysLast fall, Mylan announced it had reached a swift settlement with the U.S. Department of Justice over allegedMedicaid misclassifications on thebig-selling EpiPen. But now, a top U.S. health official s2017/2/14
-
Is Praluent doomed? Regeneron, Sanofi appeal for a reprieve, but experts are skepticalSanofi and Regeneron have made their bid for a Praluent reprieve. In the wake of a district judge’s patent ruling that could push the partners’ new cholesterol drug off the market, the two companies a2017/2/14
-
Supreme Court takes up Amgen, Sandoz's market-defining biosimilars disputeThe U.S. Supreme Court will take on a closely watched legal skirmish between Amgen and Novartis’ Sandoz, with the outcome set to define launch timelines across the budding biosim field. The Supreme2017/2/13
-
Biogen to fork over $1.25B-plus to settle blockbuster Tecfidera patent fight with ForwardBiogen has settled its Tecfidera patent fight with Forward Pharma for a whopping $1.25 billion in upfront cash. And if Forward wins particular patent rights on its rival drug, Biogen will be on the ho2017/2/13
-
Eli Lilly's Alimta escapes early generics—and a sales hit—with patent win over TevaChalk up a win for Eli Lilly in a much-watched patent tussle over the blockbuster cancer med Alimta. A federal appeals court said generic versions from Teva and others would step on a key Lilly patent2017/2/10